Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature
Applied Sciences
; 12(15):7552, 2022.
Article
in English
| ProQuest Central | ID: covidwho-1993922
ABSTRACT
Molecular profiling has revolutionized the treatment of metastatic NSCLC. Uncommon mutations have been reported primarily in EGFR and BRAF genes and are frequently associated with atypical clinical presentations. Here, we present a rare case of a patient affected by BRAF exon 15 p.K601E-mutated lung cancer with synchronous peritoneal carcinomatosis. First line treatment with chemo-immunotherapy combinations provided a PFS of 8–9 months, whereas a second line treatment with BRAF and MEK inhibitors elicited a dissociated response. The latter clinical outcome suggests that these inhibitors have only partial activity against this rare mutation.
Sciences: Comprehensive Works; lung cancer; BRAF exon 15 p.K601E; target therapy; immunotherapy; peritoneal carcinomatosis; Severe acute respiratory syndrome coronavirus 2; Cancer therapies; Mutation; Non-small cell lung carcinoma; Oxygen therapy; Medical laboratories; Thyroid gland; Dyspnea; Metastases; Sarcoma; Kinases; MEK inhibitors; Proteins; Literature reviews; Patients; Medical prognosis; Ascites; Inhibitors; Skin cancer; Thoracentesis; Melanoma; Ultrasonic imaging; Cell division
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Case report
/
Prognostic study
Language:
English
Journal:
Applied Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS